ORMP — ORAMED PHARMACEUTICALS INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1176309 ·
Last close
$3.87
Market Cap
$158.38M
52W High
$5.01
52W Low
$3.23
ADV30
201,083
Next earnings
2026-08-14
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | 0 | -3,659,000 | 38,310,000 | 268,847,000 | 13,202,000 | 30,571,000 |
| Dec 2025 | 0 | 0 | -5,672,000 | 10,009,000 | 230,864,000 | 45,947,000 | 31,120,000 |
| Sep 2025 | 0 | 0 | -2,427,000 | 48,395,000 | 220,493,000 | 52,179,000 | 18,163,000 |
| Jun 2025 | 0 | 0 | -2,489,000 | 13,288,000 | 161,684,000 | 15,797,000 | 8,101,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,541,000
Investing CF
$-37,661,000
Financing CF
$-15,105,000
CapEx
$-2,140,000
Dividends Paid
$-10,364,000
Buybacks
$-6,854,000
EPS Diluted TTM
$2.16
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-85,121,000
Inventory
—
Receivables
$0
ST Investments
$52,638,000
EBIT TTM
$78,723,000
Pretax Income TTM
$131,822,000
Interest Exp TTM
$2,558,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-14,126,000
Free Cash Flow
$250,625
Enterprise Value
$93,304,936
Total Cash
$65,840,000
Total Debt
$761,000
Shares Out
40,926,081
Trailing EPS
$2.60
Book Value
$5.82
ROE
58.2%
ROA
-4.3%
Div Yield
6.47%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,000,000 | -15,088,000 | 64,050,000 | 230,864,000 | 31,120,000 | — | -9,145,000 |
| Dec 2024 | 0 | -12,781,000 | -19,060,000 | 155,278,000 | 9,931,000 | — | -8,412,000 |
| Dec 2023 | 1,340,000 | -15,769,000 | 5,525,000 | 220,551,000 | 57,658,000 | — | -10,295,000 |
| Dec 2022 | 2,703,000 | -40,598,000 | -36,561,000 | 161,642,000 | 10,486,000 | — | -27,918,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.08
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $3.84 · call volume: 116 · put volume: 31
Expected Move to 2026-11-20:
±$1.70
(44.40%) —
implied range
$2.13 –
$5.54
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MIST | Milestone Pharmaceuticals Inc. | $158.11M | $1.27 | — |
| ENLV | Enlivex Ltd. | $161.50M | $0.67 | — |
| KZIA | KAZIA THERAPEUTICS LTD | $163.18M | $14.28 | — |
| NRXP | NRX Pharmaceuticals, Inc. | $164.35M | $3.84 | — |
| SPRO | Spero Therapeutics, Inc. | $165.02M | $2.85 | — |
News headlines (Yahoo Finance, 1h cache)
June 2026 Penny Stocks To Watch For Potential Growth
2026-06-15 18:05 · Yahoo
ORMP: Strategically Acquiring Interests in Medtech & Technology Companies
2026-06-08 13:08 · Yahoo
Spotlight On Oramed Pharmaceuticals And Two Other Prominent Penny Stocks
2026-05-13 12:05 · Yahoo
Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors
2026-04-14 18:06 · Yahoo
Oramed: Q4 Earnings Snapshot
2026-03-26 21:50 · Yahoo
Lifeward Successfully Closes on Strategic Partnership with Oramed
2026-03-25 20:10 · Yahoo
Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company
2026-03-13 12:00 · Yahoo
ORMP: Enabling Participation in Both ORMP & LFWD Businesses Expected to Enhance Shareholder Value
2026-02-26 16:10 · Yahoo
CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround
2026-02-03 15:20 · Yahoo
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
2026-02-03 15:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.